NCT05908396 - Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 29, 2023

Primary Completion Date

February 16, 2024

Study Completion Date

February 16, 2024

Conditions

Multiple Myeloma

Interventions

DRUG

IGM-2644

IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

37203

Tennessee Oncology (SCRI), Nashville

80218

Colorado Blood Cancer Institute, Denver

91010

City of Hope, Duarte

98109

Fred Hutchinson Cancer Research Center, Seattle